Bacharanianda Muthappa
Family Medicine · Clarksville, TXNPI 1396835427
Payments from drug & device makers
Across 147 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$535
- AstraZeneca$496
- Amgen$241
- Mylan Specialty L.p.$159
- Lilly USA, LLC$157
- Pfizer$131
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,764100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $535 |
| AstraZeneca | 31 | $496 |
| Amgen | 15 | $241 |
| Mylan Specialty L.p. | 8 | $159 |
| Lilly USA, LLC | 11 | $157 |
| Pfizer | 7 | $131 |
| Puma Biotechnology, Inc. | 1 | $125 |
| Novo Nordisk | 8 | $125 |
| Sunovion Pharmaceuticals Inc. | 15 | $124 |
| Merck | 3 | $109 |
| Idorsia Pharmaceuticals US Inc | 4 | $70 |
| AbbVie | 3 | $52 |
| Philips North America LLC | 2 | $46 |
| Dexcom, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 3 | $40 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Almatica Pharma LLC | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Leadiant Biosciences, Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $20 |
| Bayer | 1 | $20 |
| Eisai Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Novartis | 1 | $11 |
| Corium, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,764 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 168 | $279,611 |
| EliquisApixaban | 225 | $190,963 |
| JardianceEmpagliflozin | 185 | $185,121 |
| JanuviaSitagliptin Phosphate | 109 | $124,174 |
| OtezlaApremilast | 25 | $114,123 |
| MounjaroTirzepatide | 61 | $103,704 |
| FarxigaDapagliflozin Propanediol | 109 | $83,602 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $73,538 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 99 | $35,290 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $34,812 |
| XareltoRivaroxaban | 77 | $19,129 |
| RexultiBrexpiprazole | 13 | $18,818 |
| NuedextaDextromethorphan Hbr/Quinidine | 24 | $18,285 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $16,695 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $15,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $125 | $279,611168 claims |
| PfizerEliquis | $131 | $190,963225 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $496 | $130,908185 claims |
| MerckJanuvia | $109 | $124,174109 claims |
| AmgenOtezla | $241 | $114,12325 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $535 | $105,506147 claims |
| Lilly USA, LLCMounjaro | $157 | $103,70461 claims |
| Johnson & JohnsonXarelto | $15 | $19,12977 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $40 | $18,81813 claims |
| AbbVieRestasis | $52 | $12,50738 claims |
| NovartisEntresto | $11 | $10,64211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Clarksville
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.